Novo Nordisk A/S Stock News

Health insurers are going to offer coverage for Wegovy to Medicare patients. Beyond weight loss, Wegovy has shown it can reduce the risk of heart attacks and strokes.

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a sp

Novo Nordisk and Eli Lilly make medicines that target GLP-1, which figures in a number of ailments. A new study found that a similar drug could help treat Parkinson's.

People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don't shed a lot of weight on the medication, accord

A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the Ne

Eli Lilly and Novo Nordisk have seen demand surpass supply of their weight loss drugs. Their revenues have soared thanks to these popular products.

The healthcare sector is a constant source of innovation and growth. Yet, even amidst the spotlight on industry giants, a realm of underappreciated gems still exists.

Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.

Costco and its healthcare partner Sesame have started offering weight-loss drugs including Ozempic to Costco members. Under a $179 three-month prescription plan, members will have access to video cons

Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy

Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.

Novo Nordisk (NVO) closed at $127.55 in the latest trading session, marking a -0.66% move from the prior day.

Novo Nordisk's business is not only growing at a fast rate; it also generates impressive margins. Demand for its products is strong and could increase in the years ahead.